BRD4 PROTAC degrader enhances fulvestrant sensitivity in ER+ breast cancer via super-enhancer associated GREB1
Frontiers in Oncology · 19.05.2026 · 16
DOI: 10.3389/fonc.2026.1828900 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Oncology, online erschienen am 19.05.2026. Verfasst von Xiulei Zhang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Central Laboratory, Henan Provincial People's Hospital, Zhengzhou University, Zhengzhou, China. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Breast cancer has the highest incidence and mortality among all cancers affecting women. Fulvestrant resistance remains a major clinical challenge that limits the efficacy of endocrine therapies. BRD4, a transcriptional regulator that recognizes acetylated histones, is implicated in the pathogenesis and progression of various tumors, including breast cancer. However, its role in fulvestrant sensitivity and the therapeutic potential of targeted BRD4 degradation require further investigation.
Methods
We assessed BRD4 transcriptional activity in breast cancer and its functional role in tumor progression and endocrine sensitivity. The antitumor effect of a PROTAC-targeted BRD4 degrader, alone or in combination with fulvestrant, was evaluated in breast cancer cells. Integrated analysis of BRD4 and estrogen receptor (ER) chromatin immunoprecipitation sequencing (ChIP-seq) datasets was performed to identify co-occupied genomic regions and downstream targets. GREB1 was identified as a key effector and further validated as a super-enhancer-associated gene. The working mechanism of BRD4 PROTAC and fulvestrant was investigated through GREB1 signaling disruption.
Results
The occupancy of BRD4 at promoter regions was found to be increased in breast cancer, and its high expression indicated poor clinical outcome among ER+ breast cancer patients with endocrine therapy. A PROTAC-targeted BRD4 degrader significantly enhanced the antitumor efficacy of fulvestrant in breast cancer cells. Integrated ChIP-seq analysis revealed substantial co-occupancy of BRD4 and ER on shared pathways and identified GREB1 as a critical downstream effector regulated by a BRD4-associated super-enhancer. Mechanistically, the BRD4 PROTAC enhances fulvestrant sensitivity by down-regulation of GREB1 expression.
Conclusion
Targeting BRD4 with PROTAC degraders represents a promising therapeutic strategy in breast cancer by suppressing GREB1 expression and enhancing the efficacy of fulvestrant.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Central Laboratory, Henan Provincial People's Hospital, Zhengzhou University, Zhengzhou, China.
- Department of Clinical Laboratory, Henan Provincial People's Hospital, Zhengzhou University, Zhengzhou, China.
- Department of Breast Surgery, Henan Provincial People's Hospital, Zhengzhou University, Zhengzhou, China.
- Henan Provincial Key Medical Laboratory of Genetics, Zhengzhou University, Zhengzhou, China.
Zitieren
APA
Zhang, X., Zheng, P., Liu, Z., Zhang, Q., Duan, W., Zhang, T., & Liu, X. (2026). BRD4 PROTAC degrader enhances fulvestrant sensitivity in ER+ breast cancer via super-enhancer associated GREB1. Frontiers in Oncology, 16. https://doi.org/10.3389/fonc.2026.1828900
Vancouver
Zhang X, Zheng P, Liu Z, Zhang Q, Duan W, Zhang T, et al. BRD4 PROTAC degrader enhances fulvestrant sensitivity in ER+ breast cancer via super-enhancer associated GREB1. Frontiers in Oncology. 2026;16. doi:10.3389/fonc.2026.1828900
BibTeX
@article{Zhang2026,
author = {Zhang, Xiulei and Zheng, Peiming and Liu, Zhengyi and Zhang, Qian and Duan, Wenjing and Zhang, Tingting and Liu, Xiaozhuan},
title = {BRD4 PROTAC degrader enhances fulvestrant sensitivity in ER+ breast cancer via super-enhancer associated GREB1},
journal = {Frontiers in Oncology},
year = {2026},
volume = {16},
doi = {10.3389/fonc.2026.1828900}
}
EUVIMED